Epidemiología de la enfermedad de Parkinson

Referencias bibliográficas: 

1 Singleton AB, Farrer MJ, Bonifati V. The genetics of Parkinson’s disease: progress and therapeutic implications. Mov Disord 2013;28: 14–23.

2 Kalia LV, Lang AE. Parkinson’s disease. Lancet 2015; 386: 896–912.

3 Klein C, Westenberger A. Genetics of Parkinson’s disease. Cold Spring Harb Perspect Med 2012; 2: a008888.

4 Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002; 125: 861–70.

5 Savica R, Rocca WA, Ahlskog JE. When does Parkinson disease start? Arch Neurol 2010; 67: 798–801.

6 Park M, Ross GW, Petrovitch H, et al. Consumption of milk and calcium in midlife and the future risk of Parkinson disease. Neurology 2005; 64: 1047–51.

7 Gao X, Cassidy A, Schwarzschild MA, Rimm EB, Ascherio A. Habitual intake of dietary fl avonoids and risk of Parkinson disease. Neurology 2012; 78: 1138–45.

8 Palacios N, Fitzgerald KC, Hart JE, et al. Particulate matter and risk of Parkinson disease in a large prospective study of women. Environ Health 2014; 13: 80.

9 Palacios N, Gao X, O’Reilly E, et al. Alcohol and risk of Parkinson’s disease in a large, prospective cohort of men and women. Mov Disord 2012; 27: 980–87.

10 Bornebroek M, de Lau LM, Haag MD, et al. Nonsteroidal anti-infl ammatory drugs and the risk of Parkinson disease. Neuroepidemiology 2007; 28: 193–96.

11 Goldman SM, Kamel F, Ross GW, et al. Genetic modifi cation of the association of paraquat and Parkinson’s disease. Mov Disord 2012;27: 1652–58.

12 Hu G, Jousilahti P, Bidel S, Antikainen R, Tuomilehto J. Type 2 diabetes and the risk of Parkinson’s disease. Diabetes Care 2007;30: 842–47.

13 Saaksjarvi K, Knekt P, Mannisto S, et al. Reduced risk of Parkinson’s disease associated with lower body mass index and heavy leisure-time physical activity. Eur J Epidemiol 2014; 29: 285–92.

14 Dong J, Beard JD, Umbach DM, et al. Dietary fat intake and risk for Parkinson’s disease. Mov Disord 2014; 29: 1623–30.

15 Chen H, Mosley TH, Alonso A, Huang X. Plasma urate and Parkinson’s disease in the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol 2009; 169: 1064–69.

16 Kyrozis A, Ghika A, Stathopoulos P, Vassilopoulos D, Trichopoulos D, Trichopoulou A. Dietary and lifestyle variables in relation to incidence of Parkinson’s disease in Greece. Eur J Epidemiol 2013; 28: 67–77.

17 Driver JA, Logroscino G, Lu L, Gaziano JM, Kurth T. Use of non-steroidal anti-infl ammatory drugs and risk of Parkinson’s disease: nested case-control study. BMJ 2011; 342: d198.

18 Chen H, Ding D, Wang J, et al. Parkinson’s disease research in a prospective cohort in China. Parkinsonism Relat Disord 2015;21: 1200–04.

19 Schrag A, Horsfall L, Walters K, Noyce A, Petersen I. Prediagnostic presentations of Parkinson’s disease in primary care: a case-control study. Lancet Neurol 2015; 14: 57–64.

20 de Lau LM, Breteler MM. Epidemiology of Parkinson’s disease. Lancet Neurol 2006; 5: 525–35.

21 Wirdefeldt K, Adami HO, Cole P, Trichopoulos D, Mandel J. Epidemiology and etiology of Parkinson’s disease: a review of the evidence. Eur J Epidemiol 2011; 26 (suppl 1): S1–58.

22 Hirtz D, Thurman DJ, Gwinn-Hardy K, Mohamed M, Chaudhuri AR, Zalutsky R. How common are the “common” neurologic disorders? Neurology 2007; 68: 326–37.

23 Elbaz A, Bower JH, Maraganore DM, et al. Risk tables for parkinsonism and Parkinson’s disease. J Clin Epidemiol 2002;55: 25–31.

24 Winkler AS, Tutuncu E, Trendafi lova A, et al. Parkinsonism in a population of northern Tanzania: a community-based door-to-door study in combination with a prospective hospital-based evaluation. J Neurol 2010; 257: 799–805.

25 Dotchin C, Msuya O, Kissima J, et al. The prevalence of Parkinson’s disease in rural Tanzania. Mov Disord 2008; 23: 1567–672.

26 Okubadejo NU, Bower JH, Rocca WA, Maraganore DM. Parkinson’s disease in Africa: a systematic review of epidemiologic and genetic studies. Mov Disord 2006; 21: 2150–56.

27 Zhang ZX, Roman GC, Hong Z, et al. Parkinson’s disease in China: prevalence in Beijing, Xian, and Shanghai. Lancet 2005; 365: 595–97.

28 Tan LC, Venketasubramanian N, Jamora RD, Heng D. Incidence of Parkinson’s disease in Singapore. Parkinsonism Relat Disord 2007;13: 40–43.

29 Mayeux R, Marder K, Cote LJ, et al. The frequency of idiopathic Parkinson’s disease by age, ethnic group, and sex in northern Manhattan, 1988–1993. Am J Epidemiol 1995; 142: 820–27.

30 Van Den Eeden SK, Tanner CM, Bernstein AL, et al. Incidence of Parkinson’s disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 2003; 157: 1015–22.

31 Wright Willis A, Evanoff BA, Lian M, Criswell SR, Racette BA. Geographic and ethnic variation in Parkinson disease: a population-based study of US Medicare benefi ciaries. Neuroepidemiology 2010; 34: 143–51.

32 Horsfall L, Petersen I, Walters K, Schrag A. Time trends in incidence of Parkinson’s disease diagnosis in UK primary care. J Neurol 2013; 260: 1351–57.

33 Darweesh SK, Koudstaal PJ, Stricker BH, Hofman A, Ikram MA. Trends in the incidence of Parkinson disease in the general population: the rotterdam study. Am J Epidemiol 2016; 183: 1018–26.

34 Savica R, Grossardt BR, Bower JH, Ahlskog JE, Rocca WA. Time trends in the incidence of Parkinson disease. JAMA Neurol 2016;73: 981–89.

35 Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Influence of strict, intermediate, and broad diagnostic criteria on the age- and sex-specifi c incidence of Parkinson’s disease. Mov Disord 2000;15: 819–25.

36 Taylor KSM, Cook JA, Counsell CE. Heterogeneity in male to female risk for Parkinson’s disease. J Neurol Neurosurg Psychiatry 2007; 78: 905–06.

37 Chen H, Zhang SM, Hernan MA, Willett WC, Ascherio A. Diet and Parkinson’s disease: a potential role of dairy products in men. Ann Neurol 2002; 52: 793–801.

38 Chen H, O’Reilly E, McCullough ML, et al. Consumption of dairy products and risk of Parkinson’s disease. Am J Epidemiol 2007;165: 998–1006.

39 Saaksjarvi K, Knekt P, Lundqvist A, et al. A cohort study on diet and the risk of Parkinson’s disease: the role of food groups and diet quality. Br J Nutr 2013; 109: 329–37.

40 Jiang W, Ju C, Jiang H, Zhang D. Dairy foods intake and risk of Parkinson’s disease: a dose-response meta-analysis of prospective cohort studies. Eur J Epidemiol 2014; 29: 613–19.

41 Abbott RD, Ross GW, Petrovitch H, et al. Midlife milk consumption and substantia nigra neuron density at death. Neurology 2016;42 Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 2004; 350: 1093–103.

43 Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983; 219: 979–80.

44 Petrovitch H, Ross GW, Abbott RD, et al. Plantation work and risk of Parkinson disease in a population-based longitudinal study. Arch Neurol 2002; 59: 1787–92.

45 Baldi I, Cantagrel A, Lebailly P, et al. Association between Parkinson’s disease and exposure to pesticides in southwestern France. Neuroepidemiology 2003; 22: 305–10.

46 Ascherio A, Chen H, Weisskopf MG, et al. Pesticide exposure and risk for Parkinson’s disease. Ann Neurol 2006; 60: 197–203.

47 Weisskopf MG, Knekt P, O’Reilly EJ, et al. Persistent organochlorine pesticides in serum and risk of Parkinson disease. Neurology 2010; 74: 1055–61.

48 Tanner CM, Kamel F, Ross GW, et al. Rotenone, paraquat, and Parkinson’s disease. Environ Health Perspect 2011; 119: 866–72.

49 Guilarte TR, Nihei MK, McGlothan JL, Howard AS. Methamphetamine-induced defi cits of brain monoaminérgico neuronal markers: distal axotomy or neuronal plasticity. Neuroscience 2003; 122: 499–513.

50 Callaghan RC, Cunningham JK, Sajeev G, Kish SJ. Incidence of Parkinson’s disease among hospital patients with methamphetamine-use disorders. Mov Disord 2010; 25: 2333–39.

51 Curtin K, Fleckenstein AE, Robison RJ, Crookston MJ, Smith KR, Hanson GR. Methamphetamine/amphetamine abuse and risk of Parkinson’s disease in Utah: a population-based assessment. Drug Alcohol Depend 2015; 146: 30–38.

52 Liu R, Gao X, Lu Y, Chen H. Meta-analysis of the relationship between Parkinson disease and melanoma. Neurology 2011; 76: 2002–09.

53 Olsen JH, Friis S, Frederiksen K. Malignant melanoma and other types of cancer preceding Parkinson disease. Epidemiology 2006;17: 582–87.

54 Wirdefeldt K, Weibull CE, Chen H, et al. Parkinson’s disease and cancer: A register-based family study. Am J Epidemiol 2014; 179: 85–94.

55 Constantinescu R, Romer M, Kieburtz K, and the DATATOP Investigators of the Parkinson Study Group. Malignant melanoma in early Parkinson’s disease: the DATATOP trial. Mov Disord 2007;22: 720–22.

56 Schwid SR, Bausch J, Oakes D, et al, and the PSG PRECEPT Investigators. Cancer incidence in a trial of an antiapoptotic agent for Parkinson’s disease. Mov Disord 2010; 25: 1801–08.

57 Constantinescu R, Elm J, Auinger P, et al, and the NET-PD Investigators. Malignant melanoma in early-treated Parkinson’s disease: the NET-PD trial. Mov Disord 2014; 29: 263–65.

58 Gao X, Simon KC, Han J, Schwarzschild MA, Ascherio A. Genetic determinants of hair color and Parkinson’s disease risk. Ann Neurol 2009; 65: 76–82.

59 Gao X, Simon KC, Han J, Schwarzschild MA, Ascherio A. Family history of melanoma and Parkinson disease risk. Neurology 2009; 73: 1286–91.

60 Lubbe SJ, Escott-Price V, Brice A, et al, and the International Parkinson’s Disease Genomics Consortium. Is the MC1R variant p.R160W associated with Parkinson’s? Ann Neurol 2016; 79: 159–61.

61 Meng S, Song F, Chen H, et al. No association between Parkinson disease alleles and the risk of melanoma. Cancer Epidemiol Biomarkers Prev 2012; 21: 243–45.

62 Song F, Qureshi AA, Gao X, Li T, Han J. Smoking and risk of skin cancer: a prospective analysis and a meta-analysis. Int J Epidemiol2012; 41: 1694–705.

63 Loftfi eld E, Freedman ND, Graubard BI, et al. Coffee drinking and cutaneous melanoma risk in the NIH-AARP diet and health study. J Natl Cancer Inst 2015; 107: 10.1093/jnci/dju421.

64 Wu S, Han J, Song F, et al. Caffeine intake, coffee consumption, and risk of cutaneous malignant melanoma. Epidemiology 2015;

26: 898–908.

65 Wang H, Chen H, Gao X, et al. Telomere length and risk of Parkinson’s disease. Mov Disord 2008; 23: 302–05.

66 Schurks M, Buring J, Dushkes R, Gaziano JM, Zee RY, Kurth T. Telomere length and Parkinson’s disease in men: a nested case-control study. Eur J Neurol 2014; 21: 93–99.

67 Bajaj A, Driver JA, Schernhammer ES. Parkinson’s disease and cancer risk: a systematic review and meta-analysis. Cancer Causes Control 2010; 21: 697–707.

68 Marras C, Hincapie CA, Kristman VL, et al. Systematic review of the risk of Parkinson’s disease after mild traumatic brain injury: results of the International Collaboration on Mild Traumatic Brain Injury Prognosis. Arch Phys Med Rehabil 2014; 95 (suppl): S238–44.

68 Rugbjerg K, Ritz B, Korbo L, Martinussen N, Olsen JH. Risk of Parkinson’s disease after hospital contact for head injury: population based case-control study. BMJ 2008; 337: a2494.

70 Fang F, Chen H, Feldman AL, Kamel F, Ye W, Wirdefeldt K. Head injury and Parkinson’s disease: a population-based study. Mov Disord 2012; 27: 1632–35.

71 Gardner RC, Burke JF, Nettiksimmons J, Goldman S, Tanner CM, Yaff e K. Traumatic brain injury in later life increases risk for Parkinson disease. Ann Neurol 2015; 77: 987–95.

72 Abbott RD, Ross GW, White LR, et al. Midlife adiposity and the future risk of Parkinson’s disease. Neurology 2002; 59: 1051–57.

73 Chen H, Zhang SM, Schwarzschild MA, Hernan MA, Willett WC, Ascherio A. Obesity and the risk of Parkinson’s disease. Am J Epidemiol 2004; 159: 547–55.

74 Hu G, Jousilahti P, Nissinen A, Antikainen R, Kivipelto M, Tuomilehto J. Body mass index and the risk of Parkinson disease. Neurology 2006; 67: 1955–59.

75 Logroscino G, Sesso HD, Paff enbarger RS Jr, Lee IM. Body mass index and risk of Parkinson’s disease: a prospective cohort study. Am J Epidemiol 2007; 166: 1186–90.

76 Driver JA, Smith A, Buring JE, Gaziano JM, Kurth T, Logroscino G. Prospective cohort study of type 2 diabetes and the risk of Parkinson’s disease. Diabetes Care 2008;31: 2003–05.

77 Palacios N, Gao X, McCullough ML, et al. Obesity, diabetes, and risk of Parkinson’s disease. Mov Disord 2011; 26: 2253–59.

78 Savica R, Grossardt BR, Ahlskog JE, Rocca WA. Metabolic markers or conditions preceding Parkinson’s disease: a case-control study. Mov Disord 2012; 27: 974–79.

79 Wang YL, Wang YT, Li JF, Zhang YZ, Yin HL, Han B. Body mass index and risk of Parkinson’s disease: a dose-response meta-analysis of prospective studies. PLoS One 2015; 10: e0131778.

80 Saaksjarvi K, Knekt P, Mannisto S, Lyytinen J, Heliovaara M. Prospective study on the components of metabolic syndrome and the incidence of Parkinson’s disease. Parkinsonism Relat Disord 2015; 21: 1148–55.

81 Schernhammer E, Hansen J, Rugbjerg K, Wermuth L, Ritz B. Diabetes and the risk of developing Parkinson’s disease in Denmark. Diabetes Care 2011; 34: 1102–08.

82 Sun Y, Chang YH, Chen HF, Su YH, Su HF, Li CY. Risk of Parkinson disease onset in patients with diabetes: a 9-year population-based cohort study with age and sex stratifi cations. Diabetes Care 2012; 35: 1047–49.

83 Xu Q, Park Y, Huang X, et al. Diabetes and risk of Parkinson’s disease. Diabetes Care 2011; 34: 910–15.

84 Simon KC, Chen H, Schwarzschild M, Ascherio A. Hypertension, hypercholesterolemia, diabetes, and  risk of Parkinson disease. Neurology 2007; 69: 1688–95.

85 Kim SC, Liu J, Solomon DH. Risk of incident diabetes in patients with gout: a cohort study. Arthritis Rheum (Munch) 2015; 67: 273–80.

86 Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI. Impaired mitochondrial activity in the insulin-resistant off spring of patients with type 2 diabetes. N Engl J Med 2004; 350: 664–71.

87 Aviles-Olmos I, Limousin P, Lees A, Foltynie T. Parkinson’s disease, insulin resistance and novel agents of neuroprotection. Brain 2013;136: 374–84.

88 Santiago JA, Potashkin JA. Shared dysregulated pathways lead to Parkinson’s disease and diabetes. Trends Mol Med 2013; 19: 176–86.

89 St-Pierre J, Drori S, Uldry M, et al. Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell 2006; 127: 397–408.

90 Wahlqvist ML, Lee MS, Hsu CC, Chuang SY, Lee JT, Tsai HN. Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson’s disease occurring with Type 2 diabetes in a Taiwanese population cohort. Parkinsonism Relat Disord 2012; 18: 753–58.

91 Svenningsson P, Wirdefeldt K, Yin L, et al. Reduced incidence of Parkinson’s disease after dipeptidyl peptidase-4 inhibitors-A nationwide case-control study. Mov Disord 2016; 10.1002/mds.2673. 86: 512–19.

92 de Lau LM, Koudstaal PJ, Hofman A, Breteler MM. Serum cholesterol levels and the risk of Parkinson’s disease. Am J Epidemiol 2006; 164: 998–1002.

93 Huang X, Abbott RD, Petrovitch H, Mailman RB, Ross GW. Low LDL cholesterol and increased risk of Parkinson’s disease: prospective results from Honolulu-Asia Aging Study. Mov Disord 2008; 23: 1013–18.

94 Hu G, Antikainen R, Jousilahti P, Kivipelto M, Tuomilehto J. Total cholesterol and the risk of Parkinson disease. Neurology 2008;70: 1972–79.

95 Zhang D, Jiang H, Xie J. Alcohol intake and risk of Parkinson’s disease: a meta-analysis of observational studies. Mov Disord 2014; 29: 819–22.

96 Yamamoto T, Moriwaki Y, Takahashi S. Eff ect of ethanol on metabolism of purine bases (hypoxanthine, xanthine, and uric acid). Clin Chim Acta 2005; 356: 35–57.

97 Eriksson AK, Lofving S, Callaghan RC, Allebeck P. Alcohol use disorders and risk of Parkinson’s disease: fi ndings from a Swedish national cohort study 1972-2008. BMC Neurol 2013; 13: 190.

98 Ascherio A, Weisskopf MG, O’Reilly EJ, et al. Coffee consumption, gender, and Parkinson’s disease mortality in the cancer prevention study II cohort: the modifying effects of estrogen. Am J Epidemiol 2004; 160: 977–84.

99 Simon KC, Chen H, Gao X, Schwarzschild MA, Ascherio A. Reproductive factors, exogenous estrogen use, and risk of Parkinson’s disease. Mov Disord 2009; 24: 1359–65.

100 Rugbjerg K, Christensen J, Tjonneland A, Olsen JH. Exposure to estrogen and women’s risk for Parkinson’s disease: a prospective cohort study in Denmark. Parkinsonism Relat Disord 2013;19: 457–60.

101 Liu R, Baird D, Park Y, et al. Female reproductive factors, menopausal hormone use, and Parkinson’s disease. Mov Disord 2014; 29: 889–96.

102 Wang P, Li J, Qiu S, Wen H, Du J. Hormone replacement therapy and Parkinson’s disease risk in women: a meta-analysis of 14 observational studies. Neuropsychiatr Dis Treat 2015; 11: 59–66.

103 Ascherio A, Chen H, Schwarzschild MA, Zhang SM, Colditz GA, Speizer FE. Caffeine, postmenopausal estrogen, and risk of Parkinson’s disease. Neurology 2003; 60: 790–95.

104 Palacios N, Gao X, McCullough ML, et al. Caffeine and risk of Parkinson’s disease in a large cohort of men and women.

Mov Disord 2012; 27: 1276–82.

105 Rocca WA, Bower JH, Maraganore DM, et al. Increased risk of parkinsonism in women who underwent oophorectomy before menopause. Neurology 2008; 70: 200–09.

106 Zhang SM, Hernan MA, Chen H, Spiegelman D, Willett WC, Ascherio A. Intakes of vitamins E and C, carotenoids, vitamin supplements, and PD risk. Neurology 2002; 59: 1161–69.

107 Chen H, Zhang SM, Schwarzschild MA, et al. Folate intake and risk of Parkinson’s disease. Am J Epidemiol 2004; 160: 368–75.

108 de Lau LM, Koudstaal PJ, Witteman JC, Hofman A, Breteler MM. Dietary folate, vitamin B12, and vitamin B6 and the risk of Parkinson disease. Neurology 2006; 67: 315–18.

109 Knekt P, Kilkkinen A, Rissanen H, Marniemi J, Saaksjarvi K, Heliovaara M. Serum vitamin D and the risk of Parkinson disease. Arch Neurol 2010; 67: 808–11.

110 Ding H, Dhima K, Lockhart KC, et al. Unrecognized vitamin D3 defi ciency is common in Parkinson disease: Harvard Biomarker Study. Neurology 2013; 81: 1531–37.

111 Dexter DT, Wells FR, Lees AJ, et al. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson’s disease. J Neurochem 1989; 52: 1830–36.

112 Logroscino G, Chen H, Wing A, Ascherio A. Blood donations, iron stores, and risk of Parkinson’s disease. Mov Disord 2006;21: 835–38.

113 Logroscino G, Gao X, Chen H, Wing A, Ascherio A. Dietary iron intake and risk of Parkinson’s disease. Am J Epidemiol 2008;168: 1381–88.

114 Chen H, Zhang SM, Hernan MA, Willett WC, Ascherio A. Dietary intakes of fat and risk of Parkinson’s disease. Am J Epidemiol 2003;157: 1007–14.

115 de Lau LM, Bornebroek M, Witteman JC, Hofman A, Koudstaal PJ, Breteler MM. Dietary fatty acids and the risk of Parkinson disease: the Rotterdam study. Neurology 2005; 64: 2040–45.

116 Tan LC, Koh WP, Yuan JM, et al. Diff erential eff ects of black versus green tea on risk of Parkinson’s disease in the Singapore Chinese Health Study. Am J Epidemiol 2008; 167: 553–60.

117 Abbott RD, Ross GW, White LR, et al. Environmental, life-style, and physical precursors of clinical Parkinson’s disease: recent fi ndings from the Honolulu-Asia Aging Study. J Neurol 2003;250 (suppl 3): III30–39.

118 Gardener H, Gao X, Chen H, Schwarzschild MA, Spiegelman D, Ascherio A. Prenatal and early life factors and risk of Parkinson’s disease. Mov Disord 2010; 25: 1560–67.

119 Sasco AJ, Paff enbarger RS Jr. Measles infection and Parkinson’s disease. Am J Epidemiol 1985; 122: 1017–31.